Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2014

Conditions
Interstitial Cystitis
Interventions
DRUG

LiRIS 400 mg

LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.

OTHER

LiRIS Placebo

LiRIS Placebo contains lactose, inactive substance.

Trial Locations (17)

11040

North Shore - Long Island Jewish Heath System - Monter Cancer Center, New Hyde Park

12550

Premier Medical Group of the Hudson Valley PC, Newburgh

12601

Premier Medical Group of the Hudson Valley PC, Poughkeepsie

27103

Wake Forest Baptist Health, Winston-Salem

27403

Alliance Urology Specialists, PA, Greensboro

29425

Medical University of South Carolina, Charleston

29572

Carolina Urologic Research Center, Myrtle Beach

32114

Atlantic Urological Associates, Daytona Beach

37920

Volunteer Research Group, University of Tennessee Medical Center, Knoxville

44109

MetroHealth Medical Center, Cleveland

48073

William Beaumont Hospitals, Royal Oak

49503

Female Pelvic Medicine & Urogynecology Institute of MI, Grand Rapids

66160

University of Kansas Medical Center, Kansas City

91741

Citrus Valley Medical Research , Inc., Glendora

66209-2002

The UrogynecologyCenter, LLC, Overland Park

V2S 3N6

Exdeo Clinical Research Inc., Abbotsford

K7L 3J7

Centre for Applied Urological Research, Kingston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

TARIS Biomedical, Inc.

INDUSTRY

lead

Allergan

INDUSTRY

NCT01824303 - Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis | Biotech Hunter | Biotech Hunter